

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Duff et al.

Application No.: 09/247,874

Filed: February 10, 1999

For: *Therapeutics and Diagnostics Based  
on a Novel IL-1B Mutation*

Customer Number: 25181




Art Unit: 1632

Examiner:  
Schnizer, R.



**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Label No. EL 046 632 595 US, in an envelope addressed to: Box AF, Commissioner for Patents, Washington, DC 20231, on March 2, 2001.

  
Robert King

BOX AF  
Commissioner for Patents  
Washington, DC 20231

**AMENDMENTS TO THE CLAIMS**

RECEIVED  
MAR 09 2001  
TECH CENTER 1600 2900

In this paper, Applicants present the amendments to the claims with insertions underlined and deletions bracketed. Claims not amended are not shown. A clean set of all the claims as now pending is presented in the accompanying response to office action.

**IN THE CLAIMS:**

1. (**Amended**) A method for determining a subject's susceptibility to developing [a] an inflammatory disease or condition[, which is caused by or contributed to by an inappropriately high level of IL-1 $\beta$ ], comprising the steps of detecting an IL-1B allele (+6912) or an allele in